Indaptus Therapeutics Inc (INDP) - Total Liabilities
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has total liabilities worth $615.43K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INDP asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Indaptus Therapeutics Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Indaptus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Indaptus Therapeutics Inc (INDP) total assets.
Indaptus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Indaptus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silkroad Visual Technology Co Ltd
SHE:300556
|
China | CN¥1.09 Billion |
|
Beetaloo Energy Australia Limited
AU:BTL
|
Australia | AU$40.05 Million |
|
TruBridge Inc.
NASDAQ:TBRG
|
USA | $219.05 Million |
|
Transcontinental Inc
TO:TCL-A
|
Canada | CA$815.10 Million |
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
USA | $164.15 Million |
|
Kingsway Corporation
NYSE:KWY
|
USA | $195.49 Million |
|
Valid Soluções S.A
SA:VLID3
|
Brazil | R$1.14 Billion |
|
TTS (TRANSPORT TRADE SERVICES)
RO:TTS
|
Romania | RON316.89 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Indaptus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See INDP net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indaptus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual total liabilities of Indaptus Therapeutics Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.16 Million | +81.46% |
| 2024-12-31 | $3.39 Million | +19.19% |
| 2023-12-31 | $2.85 Million | -17.07% |
| 2022-12-31 | $3.43 Million | -26.59% |
| 2021-12-31 | $4.68 Million | +132.05% |
| 2020-12-31 | $2.02 Million | -79.32% |
| 2019-12-31 | $9.74 Million | +22.35% |
| 2018-12-31 | $7.96 Million | +38.59% |
| 2017-12-31 | $5.75 Million | +184.93% |
| 2016-12-31 | $2.02 Million | +22.59% |
| 2015-12-31 | $1.65 Million | -45.50% |
| 2014-12-31 | $3.02 Million | -31.16% |
| 2013-12-31 | $4.39 Million | +377.57% |
| 2012-12-31 | $918.23K | -28.80% |
| 2011-12-31 | $1.29 Million | +25.12% |
| 2010-12-31 | $1.03 Million | -40.06% |
| 2009-12-31 | $1.72 Million | -59.63% |
| 2008-12-31 | $4.26 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more